Similar articles for PMID: 22782294

Year	Number of Results
2003	1
2006	1
2007	2
2008	1
2009	5
2010	4
2011	10
2012	15
2013	23
2014	18
2015	13
2016	7
2017	13
2018	5
2019	5
2020	7
2021	5
2022	2
2024	0

1

Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis.

Drucker AM, Wu S, Dang CT, Lacouture ME. Drucker AM, et al. Breast Cancer Res Treat. 2012 Sep;135(2):347-54. doi: 10.1007/s10549-012-2157-7. Epub 2012 Jul 11. Breast Cancer Res Treat. 2012. PMID: 22782294 Review.

2

Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.

Chung C, Lam MS. Chung C, et al. Am J Health Syst Pharm. 2013 Sep 15;70(18):1579-87. doi: 10.2146/ajhp120735. Am J Health Syst Pharm. 2013. PMID: 23988598 Review.

3

Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.

De Mattos-Arruda L, Cortes J. De Mattos-Arruda L, et al. Adv Ther. 2013 Jul;30(7):645-58. doi: 10.1007/s12325-013-0043-2. Epub 2013 Jul 24. Adv Ther. 2013. PMID: 23881722 Review.

4

Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.

Kawajiri H, Takashima T, Kashiwagi S, Noda S, Onoda N, Hirakawa K. Kawajiri H, et al. Expert Rev Anticancer Ther. 2015 Jan;15(1):17-26. doi: 10.1586/14737140.2015.992418. Epub 2014 Dec 12. Expert Rev Anticancer Ther. 2015. PMID: 25494663 Review.

5

Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis.

Su X, Lacouture ME, Jia Y, Wu S. Su X, et al. Oncology. 2009;77(2):124-33. doi: 10.1159/000229752. Epub 2009 Jul 22. Oncology. 2009. PMID: 19622903 Review.

6

Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial.

R Ferreira A, Ferreira S, Lambertini M, Maurer C, Martel S, Costa L, Ponde N, de Azambuja E. R Ferreira A, et al. Eur J Cancer. 2021 Feb;144:351-359. doi: 10.1016/j.ejca.2020.11.023. Epub 2020 Dec 31. Eur J Cancer. 2021. PMID: 33388492

7

Pertuzumab in HER2-positive breast cancer.

Sendur MA, Aksoy S, Altundag K. Sendur MA, et al. Curr Med Res Opin. 2012 Oct;28(10):1709-16. doi: 10.1185/03007995.2012.728132. Epub 2012 Oct 11. Curr Med Res Opin. 2012. PMID: 22953713 Review.

8

[Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].

Sabatier R, Gonçalves A. Sabatier R, et al. Bull Cancer. 2014 Jul-Aug;101(7-8):765-71. doi: 10.1684/bdc.2014.1940. Bull Cancer. 2014. PMID: 25091659 French.

9

Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer.

O'Sullivan CC, Swain SM. O'Sullivan CC, et al. Expert Opin Biol Ther. 2013 May;13(5):779-90. doi: 10.1517/14712598.2013.783007. Epub 2013 Mar 27. Expert Opin Biol Ther. 2013. PMID: 23530718 Review.

10

Pertuzumab: development beyond breast cancer.

Barthélémy P, Leblanc J, Goldbarg V, Wendling F, Kurtz JE. Barthélémy P, et al. Anticancer Res. 2014 Apr;34(4):1483-91. Anticancer Res. 2014. PMID: 24692675 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

114 results

Results by year